Home › All Companies › ATYR › Annual Report

aTYR PHARMA INC (ATYR) — Annual Report

AI-Powered SEC Filing Analysis

← All ATYR filings
Latest Annual Report Filed: 2026-03-05

Key Insights

  • aTYR PHARMA INC reported a significant increase in license and collaboration revenues in 2025, likely driven by its partnership with Kyorin Pharmaceutical Co Ltd.
  • The company's balance sheet remains strong, with a substantial amount of short-term investments and commercial paper holdings as of the end of 2025.
  • aTYR PHARMA continues to invest heavily in research and development, with R&D expenses increasing year-over-year, which may impact the company's profitability in the near term.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for aTYR PHARMA INC

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.